Clinical Trials | April 30, 2026
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
The Danish biotech company confirmed the global study will begin in the second half of 2026
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Subscribe To Our Newsletter & Stay Updated
